Trial Profile
Clinical Study to Assess Efficacy and Safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Jan 2024
Price :
$35
*
At a glance
- Drugs Tumour infiltrating lymphocytes (Primary) ; Cyclophosphamide; Fludarabine; Interleukin-2
- Indications Adenocarcinoma; Carcinoma; Colorectal cancer; Osteosarcoma; Ovarian cancer; Pancreatic cancer; Sarcoma
- Focus Therapeutic Use
- 08 Jan 2024 Planned End Date changed from 1 Jan 2025 to 31 Jan 2025.
- 08 Jan 2024 Planned primary completion date changed from 1 Jan 2024 to 31 Jan 2025.
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology